Advertisement
Canada markets closed

  • S&P/TSX

    22,814.81
    +206.78 (+0.91%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • DOW

    40,589.34
    +654.27 (+1.64%)
     

  • CAD/USD

    0.7229
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     

  • Bitcoin CAD

    95,190.16
    +2,039.72 (+2.19%)
     

  • CMC Crypto 200

    1,389.80
    +59.20 (+4.45%)
     

  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     

  • RUSSELL 2000

    2,260.07
    +37.09 (+1.67%)
     

  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     

  • NASDAQ

    17,357.88
    +176.16 (+1.03%)
     

  • VOLATILITY

    16.39
    -2.07 (-11.21%)
     

  • FTSE

    8,285.71
    +99.36 (+1.21%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • CAD/EUR

    0.6654
    -0.0013 (-0.19%)
     

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

Vir Biotechnology, Inc.
·1 min read
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

CONTACT: Contact: Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189